U-Neuron Biomedical (ROCO:6973) Accounts Receivable : NT$2.11 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is U-Neuron Biomedical Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. U-Neuron Biomedical's accounts receivables for the quarter that ended in Dec. 2023 was NT$2.11 Mil.

Accounts receivable can be measured by Days Sales Outstanding. U-Neuron Biomedical's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 25.62.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. U-Neuron Biomedical's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was NT$15.25.

U-Neuron Biomedical Accounts Receivable Historical Data

The historical data trend for U-Neuron Biomedical's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

U-Neuron Biomedical Accounts Receivable Chart

U-Neuron Biomedical Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

1.98

1.16

2.05

2.11

U-Neuron Biomedical Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Receivable	1.16	-	2.05	2.42	2.11

U-Neuron Biomedical Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

U-Neuron Biomedical Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

U-Neuron Biomedical's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	2.109	/	15.023	*	91
=	25.62

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), U-Neuron Biomedical's accounts receivable are only considered to be worth 75% of book value:

U-Neuron Biomedical's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(475.957	+	0.75 * 2.109	+	0.5 * 8.821	-	31.202
-	0	-	0)	/	29.55
=	15.25

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

U-Neuron Biomedical Accounts Receivable Related Terms

Thank you for viewing the detailed overview of U-Neuron Biomedical's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

U-Neuron Biomedical (ROCO:6973) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » U-Neuron Biomedical Inc (ROCO:6973) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

https://en.u-neuron.com

U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.

U-Neuron Biomedical (ROCO:6973) Headlines

No Headlines